Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EHA 2020 | Final results of BRIGHT AML 1003

Michael Heuser • 12 Jun 2020
EHA 2020
Acute Myeloid Leukemia Leukemia Myelodysplastic Syndromes Cytarabine Glasdegib
BRIGHT AML 1003

Michael Heuser, MD, of Hannover Medical School, Hannover, Germany, discusses final 4-year overall survival results of BRIGHT AML 1003 (NCT01546038), a study investigating survival benefit of glasdegib plus low-dose cytarabine in acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).

More from Michael Heuser

3:01
BAY1436032: IDH1 inhibition in IDH1-mutated AML
Michael Heuser • 2 Jun 2020
3:13
Is MRD monitoring prior to allograft standard in AML?
Michael Heuser • 25 Oct 2019
2:51
AML: mutant IDH1 inhibitor HMS-101
Michael Heuser • 25 Oct 2019
1:30
The clinical application of MRD testing in AML
Michael Heuser • 1 Jun 2019

Related Videos

1:25
The role of the bone marrow microenvironment in hematological malignancies
Manja Wobus • 17 Apr 2024
4:25
The challenges with accurately diagnosing and risk-stratifying patients with MDS
Klaus Metzeler • 16 Apr 2024
1:49
The unmet needs of patients with VEXAS syndrome
Maël Heiblig • 17 Apr 2024
2:31
Emerging treatment options for patients with ESA-refractory MDS: luspatercept & imetelstat
Eva Hellström-Lindberg • 11 Apr 2024
The content of VJHemOnc is intended for healthcare professionals